

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

(Use as many sheets as necessary)

Sheet

1

of

3

Application Number

10/645.215

Filing Date

August 21, 2003

First Named Inventor

Guenther ADOLF et al

Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

1/1383

U. S. PATENT DOCUMENTS

Examiner
Initials*

FOREIGN PATENT DOCUMENTS


**Examiner
Initials***

**Examiner
Signature**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/645,215		
		Filing Date	August 21, 2003		
		First Named Inventor	Guenther ADOLF, et al		
		Art Unit	To be assigned		
		Examiner Name	To be assigned		
Sheet	2	of	3	Attorney Docket Number	1/1383

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SSH		C. LIU ET AL; Cure of large human colon cancer xenografts by a C242-Maytansinoid conjugate; April 24, 1996, Vol. 2 page 466-467; ImmunoGen Inc. Cambridge MA.	
SSH		SUZANNE SMITH; Technology evaluation: C242-DM1, ImmunoGen Inc; Current Opinion in Molecular Therapeutics Vol.3(2) page 198-203 dated 2001; Pharma Press Ltd ISSN 1464-8431	
SSH		MATTHEW J. SCHIBLER ET AL; Maytanise-resistant mutants of Chinese hamster ovary cells with an alteration in alpha-tubulin; Cell Biol. Vol 63 page 503-510 September 13, 1984; Division of Endocrinology, University of Texas Medical School P.O. 20708 Houston TX. 77225	
SSH		RADHEY S. GUPTA; Cross-Resistance of Vinblastine- and Taxol-Resistant Mutants of Chinese Hamster Ovary Cells to Other Anticancer Drugs; Cancer Treatment Reports Vol. 69 No. 5 page 515-521 May 5, 1985; Dept. of Biochemistry McMaster Univ. Hamilton Ontario Canada	
SSH		JOHN J. CORREIA; Effects of Antimitotic Agents on Tubulin-Nucleotide Interactions; Pharmac Ther. Vol. 52 page 127-147, 1991; Department of Biochemistry University of Mississippi Medical Center 2500 North Street Jackson, MS. 39216	
SSH		ALLAN JORDAN ET AL; Tubulin as a Target for Anticancer Drugs: Agents which Interact with the Mitotic Spindle; Cancer Research Vol. 38 Page 259-296 dated 1998; Department of Chemistry Univ. of Manchester Inst. of Science and Tech. P.O. 88, Manchester M60 1OD, UK	
SSH		JOEP W.G. STROOMER ET AL; Safety and Biodistribution of 99mTechnetium-labeled Anti-CD44v6 Monoclonal Antibody BIWA 1 in Head and Neck Cancer Patients; Clinical Cancer Research Vol. 6 page 3046-3055, August 2000; Dept of Otolaryngology/Head and Neck Surgery Nuclear Medicine Free University Hospital, Amsterdam, The Netherlands	
SSH		European Search Report for European Counterpart EP 02018686 of the instant application. August 18, 2003.	

Examiner Signature		Date Considered	8/13/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)

Approved for use through 08/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number

10/645,215

Filing Date

August 21, 2003

First Named Inventor

Guenther ADOLF et al

Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

1/1383

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SSH		DIANNE L. NEWTON ET AL; Anti-tumor ribonuclease, combined with or conjugated to monoclonal antibody MRK16, overcomes multidrug resistance to vincristine in vitro and in vivo; International Journal of Oncology Vol. 8 page 1095-1104, 1996; BCDP, SAIC, Frederick MD 21702	
SSH		K. FOWERS; Targeting of HPMa Copolymer-Drug Conjugates to A2780/AD Ovarian Cancer Cells Using Anti-P-Glycoprotein Antibodies of Fragments; Int'l Symp. Control. Rel. Bioact. Mater. 26 Vol. 7 page 527-528, 1999; Department of Bioengineering University of Utah Salt Lake City, Utah 84112	
SSH		WU MIN; Potent Deglycosylated Ricin A Chain Immunotoxins Specifically Killing of Xenotropic Murine Retrovirus - Infected Cells; Chinese Medical Journal Vol. 5 page 383-385, 1994; Department of Pathology, Tohoku University School of Medicine, Sendai 980, Japan	
SSH		ROM E. ELIAZ; Liposome-encapsulated Doxorubicin Targeted to CD44: A Strategy to Kill CD44 overexpressing Tumor Cells; Cancer Research Vol. 61 page 2592-2601 March 15, 2001; Dept. of Biopharmaceutical Sciences and Pharmaceutical Chemistry School of Pharmacy University of San Francisco CA. 94143-0448	
SSH		K.H. HEIDER; Splice Variants of the Cell Surface Glycoprotein CD44 Associated with Metastatic Tumor Cells are Expressed in Normal Tissues of Humans and Cynomolgus Monkeys; European Journal of Cancer Vol. 31A page 2385-2391, 1995; Boehringer Ingelheim Research and Development, Vienna, Austria Department of Pathology	
SSH		K.H. HEIDER; Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas; Cancer Immunol Immunother Vol. 43 page 245-253, 1996; Boehringer Ingelheim Research and Development Bender & Co. GesmbH, Vienna Austria	
SSH		RAVI V.J. CHARI; Immunoconjugates Containing Novel Maytansinoids Anticancer Drugs; Cancer Research Vol. 52 page 127-131 January 1, 1992; ImmunoGen Inc. Cambridge Mass. 02142	
SSH		CHANGNIAN LIU ET AL; The development of antibody delivery systems to target cancer with highly potent maytansinoids; Exp. Opin. Invest. Drugs Vol. 6(2) page 169-172, 1997; Ashley Publications Ltd. ISSN 1354-3784	
SSH		CHANGNIAN LIU; Eradication of large colon tumor xenografts by targeted delivery of maytansinoids; Proc. Natl. Acad. Sc. USA Vol. 93 page 8618-8623 August 1996; ImmunoGen Inc. 148 Sidney Street Cambridge MA 02139-4239	
SSH		CLAUDE MONNERET ET AL; Ciblage de molecules antitumorales par les anticorps monoclonaux; Bull Cancer Vol. 87 (11) page 829-838, 2000; Institut Curie, 26 rue d'Ulm 75248 Paris Cedex 05	

Examiner
Signature

Date
Considered

8/13/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.